Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137001 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Daisuke Shimizu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hiroshima University Hospital, Hiroshima 734-0037, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cancer-Associated Fibroblasts, Immune Checkpoint Inhibitors, Cell Differentiation. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are known to play supportive roles in tumor development and progression, but their interactions in colorectal cancer (CRC) remain unclear. Here, we investigated the effects of colon-cancer-derived CAFs on TAM differentiation, migration, and tumor immunity, both in vitro and in vivo. When co-cultured with monocytes, CAFs attracted monocytes and induced their differentiation into M2 macrophages. Immunohistology of surgically resected human CRC specimens and orthotopically transplanted mouse tumors revealed a correlation between numbers of CAFs and numbers of M2 macrophages. In a mouse model of CRC orthotopic transplantation, treatment with an inhibitor of the colony-stimulating factor-1 receptor (PLX3397) depleted M2 macrophages and increased CD8-positive T cells infiltrating the tumor nest. While this treatment had a minor effect on tumor growth, combining PLX3397 with anti-PD-1 antibody significantly reduced tumor growth. RNA-seq following combination therapy showed activation of tumor immunity. In summary, CAFs are involved in the induction and mobilization of M2 macrophage differentiation in the CRC tumor immune microenvironment, and the combination of cancer immunotherapy and PLX3397 may represent a novel therapeutic option for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hiroshima University Hospital, Hiroshima 734-0037, Japan.
ORCID-Profile: Hidehiko Takigawa
Zitieren
APA
Shimizu, D., Yuge, R., Kitadai, Y., Ariyoshi, M., Miyamoto, R., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024). Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137001
Vancouver
Shimizu D, Yuge R, Kitadai Y, Ariyoshi M, Miyamoto R, Hiyama Y, et al. Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137001
BibTeX
@article{Shimizu2024,
author = {Shimizu, Daisuke and Yuge, Ryo and Kitadai, Yuki and Ariyoshi, Misa and Miyamoto, Ryo and Hiyama, Yuichi and Takigawa, Hidehiko and Urabe, Yuji and Oka, Shiro},
title = {Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137001}
}
EUVIMED